Skip to content


Chantix, Champix (varenicline) is a small molecule pharmaceutical. Varenicline was first approved as Chantix on 2006-09-25. It has been approved in Europe to treat tobacco use cessation. The pharmaceutical is active against neuronal acetylcholine receptor subunit alpha-4. In addition, it is known to target neuronal acetylcholine receptor subunit alpha-3.
Trade Name Champix
Common Name Varenicline
Indication tobacco use cessation
Drug Class Nicotinic acetylcholine receptor partial agonists/agonists
Get full access now